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Abstract
Background: Calcitonin gene related peptide (CGRP) is a neuropeptide that is abundant in the sensory neurons which
innervate bone. The effects of CGRP on isolated bone cells have been widely studied, and CGRP is currently considered to
be an osteoanabolic peptide that has effects on both osteoclasts and osteoblasts. However, relatively little is known about
the physiological role of CGRP in-vivo in the skeletal responses to bone loading, particularly fatigue loading.
Methodology/Principal Findings: We used the rat ulna end-loading model to induce fatigue damage in the ulna unilaterally
during cyclic loading. We postulated that CGRP would influence skeletal responses to cyclic fatigue loading. Rats were fatigue
loaded and groups of rats were infused systemically with 0.9% saline, CGRP, or the receptor antagonist, CGRP8–37, for a 10 day
study period. Ten days after fatigue loading, bone and serum CGRP concentrations, serum tartrate-resistant acid phosphatase
5b (TRAP5b) concentrations, and fatigue-induced skeletal responses were quantified. We found that cyclic fatigue loading led
to increased CGRP concentrations in both loaded and contralateral ulnae. Administration of CGRP8–37 was associated with
increasedtargeted remodelingin the fatigue-loadedulna. Administrationof CGRP or CGRP8–37both increased reparative bone
formation over the study period. Plasma concentration of TRAP5b was not significantly influenced by either CGRP or CGRP8–37
administration.
Conclusions: CGRP signaling modulates targeted remodeling of microdamage and reparative new bone formation after
bone fatigue, and may be part of a neuronal signaling pathway which has regulatory effects on load-induced repair
responses within the skeleton.
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Introduction
The failure of repair responses to protect the skeleton from
fracture is an important problem, but the physiological pathways
that regulate skeletal responses to loading are not fully understood.
Fractures resulting from osteoporosis were estimated to cost the
U.S.A. $17 billion in 2005, a number that is expected to rise nearly
50% by 2025 [1]. In addition to osteoporotic fracture, stress
fractures are also common in military recruits and other human,
canine and equine athletes, where bone fatigue can overwhelm
repair mechanisms, with associated accumulation of fatigue
damage within bone and development of a stress fracture [2–4].
Functional adaptation of the skeleton is thought to consist
primarily of two processes, modeling and remodeling [5]. Bone
modelingchangesthespatialdistributionofbone,whileremodelingis
a process of bone removal and replacement [5]. In situations where
fatigue damage is present within bone, repair responses include
targeted remodeling of microdamage [6] and woven bone formation
on adjacent bone surfaces. Load-induced skeletal responses are
thought to be locally regulated by bone cells [7,8]. However, recent
work also suggests that the sensory innervation of bone may have
regulatory effects on skeletal responses to bone loading [9,10].
The nervous system plays a role in the regulation of skeletal
metabolism [11]. The sensory innervation of bone also has an
important role in nociception and development of bone pain [12].
However, little work to date has addressed whether or not the
innervation of bone has a functional role in the physiological
responses of bone to loading. Periosteum, endosteum, and bone
tissue are all innervated by nerve fibers [13–15]. This innervation
exhibits plasticity in response to mechanical loading, in that a
single loading event results in persistent changes in neuropeptide
concentrations in both loaded and distant long bones, as well as
changes in the neural circuits between limbs [9,10]. Of the three
compartments of long bones, the periosteum has a particularly
dense innervation, which is arranged in a net-like meshwork
optimized for the detection of mechanical distortion [12]. This
innervation is primarily peptidergic, and contains both sensory
and sympathetic fibers [12,16,17]. Individual bone cells are
directly connected to the nervous system via unmyelinated sensory
neurons [18]. Bone cells express a range of functional neurotrans-
mitter receptors and transporters, including those for calcitonin
gene related peptide (CGRP) [19–21].
The calcitonin family of peptides has been extensively studied in
bone over the past few years because of their effects on bone cells
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on bone cells; both osteoclasts and osteoblasts have functional
receptors for CGRP [20–22]. Physiological actions of CGRP are
mediated through a family of type II G-protein coupled receptors,
the most important of which is the CGRP1 receptor [20,23,24]. In
vitro, CGRP inhibits maturation of osteoclasts [25] and bone
resorption [26], and is anabolic to osteoblasts by stimulation of
canonical Wnt signaling and by inhibition of osteoblast apoptosis
[21,27]. CGRP has two isoforms, CGRP-a and CGRP-b. In the
rat, CGRP-a and CGRP-b differ by only one amino acid, despite
being derived from separate genes, Calca and Calcb, respectively
[28]. CGRP-a increases the proliferation rate of osteoblasts
[27,29], prevents bone loss when delivered systemically to
ovariectomized rats [30], and increases bone mass in transgenic
mice with an osteoblast-specific promoter that over-expresses
CGRP-a [31]. CGRP-a knockout mice are osteopenic [32].
Collectively, these findings suggest that CGRP-a is a peptide with
osteoanabolic activity in-vivo. Unlike CGRP-a, CGRP-b is not
considered osteogenic [33].
In the present study, our goal was to determine whether bone
CGRP concentrations were modulated by cyclic fatigue loading in
vivo. An increase would be expected with an osteoanabolic effect in
a bone formation model, although earlier work suggests that short
periods of loading without fatigue are associated with reduced
CGRP concentrations in bone [9]. Using the fatigue loading
model, we also sought to determine whether manipulation of
systemic CGRP signaling in vivo would limit osteoclast activation
for remodeling and increase reparative osteogenesis.
Materials and Methods
Animals
A homogeneous group of 68 actively growing male Sprague-
Dawley rats (body weight 292–305 g, aged 67614 days) was used
for the study. Rats were provided with food and water ad libitum.
All procedures were performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health and the
American Veterinary Medical Association and with approval from
the Animal Care Committee of the University of Wisconsin-
Madison. Ulna loading was performed under isoflurane anesthesia
with butorphanol analgesia. Humane euthanasia was performed
under isoflurane anesthesia at the end of the experimental period,
using an intracardiac injection of pentobarbitone.
Experimental design
To determine the effect of unilateral ulna fatigue loading on
CGRP peptide concentrations in the thoracic limb long bones, 12
rats were fatigue loaded until 40% loss of stiffness was attained,
using an initial peak strain of 23,000 me (Fatigue group). An
additional 24 rats were used as controls: 12 rats were sham
controls (Sham group), and thus given the same treatment regimen
as rats in the treatment groups, but without being subjected to any
mechanical loading; 12 rats served as baseline controls (Baseline
group). Rats were euthanatized 10 days after loading or sham
loading.
To determine how manipulation of systemic CGRP signaling
might influence skeletal repair responses to fatigue loading, 32 rats
were assigned one of 3 treatment groups. The right ulna of all rats
was fatigue loaded until 40% of stiffness was attained, using an
initial peak strain of 23,000 me. Immediately after loading, an
osmotic pump (Alzet Corporation, Cupertino, CA) was implanted
subcutaneously dorsally between the scapulae to provide a
continuous infusion of either saline, CGRP, or the CGRP1
receptor antagonist CGRP8–37 [23,34], for the duration of the
study. The 8 rats assigned to the Saline group received 40 ml/kg/
day 0.9% saline. The 12 rats assigned to the CGRP group received
100 mg/kg/day of CGRP [35] and the 12 rats assigned to the
CGRP8–37 group received 100 mg/kg/day of CGRP8–37 [36]. All
rats were additionally given an intraperitoneal injection of calcein
(7 mg/kg) immediately after fatigue loading and again 7 days later
to label load-induced bone formation. Rats were euthanatized 10
days after loading.
In-vivo ulnar fatigue loading
In-vivo fatigue loading of the right ulna was performed under
isoflurane-induced general anesthesia. The right antebrachium of
each rat was placed horizontally between two loading cups, which
were fixed to the loading platen and actuator of a materials testing
machine (Model 8800 DynaMight; Instron, Canton, MA, USA)
with a 250N load cell (Honeywell Sensotec, Canton, MA, USA).
The right ulna then underwent cyclic loading by means of axial
compression, which accentuates the pre-existing mediolateral
curvature of the diaphysis of the rat ulna, translating most of the
axial force into a bending moment (Fig. 1). Cyclic fatigue loading
was performed at 4 Hz, and was initiated at 216N. To induce
fatigue, the load applied to the ulna was incrementally increased
until fatigue was initiated, as indicated by increasing displacement
amplitude from a stable baseline. Loading was then terminated
when 40% loss of stiffness was attained.
Quantification of plasma and bone CGRP and plasma
TRAP5b
At the time of euthanasia, plasma blood samples were collected
and left and right ulnae were dissected with surrounding tissue; all
samples were stored at 280uC until processing. Bones were placed
in liquid nitrogen and pulverized using a ball-mill grinder (Mikro-
Dismembrator S; Sartorius Stedim Biotech, Aubagne Cedex,
France). After homogenization, the samples were centrifuged at
3,000 g for 15 min. The supernatants were freeze-dried and
dissolved in ELISA buffer. Plasma and bone CGRP concentra-
tions were determined using a rat-specific ELISA assay (Cayman
Figure 1. Schematic diagram of the rat ulna loading model. The
antebrachium was placed horizontally in loading cups attached to a
materials testing machine. The medio-lateral diaphyseal curvature of
the rat ulna is accentuated through axial compression, most of which is
translated into a bending moment, which is greatest at ,60% the total
bone length measured from the proximal end of the ulna [37]. Ulnae
underwent cyclic fatigue loading, initiated at 23,000 me,w i t h
incremental increases in load until fatigue was initiated. Loading was
then terminated when 40% loss of stiffness was attained. Reproduced
from [43] with permission from John Wiley & Sons.
doi:10.1371/journal.pone.0020386.g001
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were also determined for both plasma and bone (BCA Protein
assay, Thermo Scientific, Rockford, IL, USA). Plasma TRAP5b
concentrations were determined using an ELISA kit validated for
the rat (Immunodiagnostic Systems Ltd, Fountain Hills, AZ,
USA). For each sample, CGRP and TRAP5b concentrations were
normalized to the total protein concentration.
Bone Histomorphometry
The pairs of ulnae and humeri were dissected along with
surrounding tissue. Fluorochrome labeled bones were dehydrated
in a graded series of ethanol (70%, 100%), bulk stained with
Villanueva’s solution for 3 days, and then embedded in
methylmethacrylate. Transverse calcified sections, 125 mm thick,
were made and mounted on standard microscope slides. Ulnae
were sectioned at 60% of total bone length measured from the
proximal end, where it has been shown maximal adaptation
occurs with this model [37]. Humeri were sectioned at the mid-
diaphysis (50% of total bone length). Confocal microscopy (MRC-
1024 Laser Scanning Confocal Microscope; Bio-Rad, Hercules,
CA, USA) was used to collect fluorescent images of each bone
section. Periosteal and endosteal labeled bone areas (Ps.L.B.Ar and
Es.L.B.Ar, %) were determined using a standard method [38], and
total cortical bone area (Tt.L.B.Ar, %) was also determined by
Figure 2. CGRP or CGRP8–37 administration did not influence plasma TRAP5b in vivo. Plasma concentrations of CGRP and TRAP5b,
normalized to plasma total protein, 10 days after fatigue loading. (A) Rats in the CGRP group had higher plasma CGRP concentrations when
compared to rats in the Saline and CGRP8–37 groups. No differences were seen between the Saline group and the CGRP8–37 group. (B) Administration
of CGRP or CGRP8–37 did not have an effect on plasma TRAP5b levels. Error bars represent standard error of the mean. Saline group, n=8; CGRP group
n=12; CGRP8–37 group, n=12.
doi:10.1371/journal.pone.0020386.g002
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measurements were made by a single observer (SJS). Data were
normalized to the original cortical area to account for minor
variations in rat size. Using the same sections, resorption space
number density and microcrack surface density (Rs.Sp.Dn, #/
mm
2; Cr.S.Dn, mm/mm
2, respectively) were also determined in
the left and right ulnae by assessment of Villanueva staining using
bright-field microscopy.
Statistical Analysis
The Kolmogorov-Smirnov test was used to confirm that data
were normally distributed. Limbs were treated as separate
experiments. Group differences in normalized bone CGRP
concentrations, normalized plasma CGRP and TRAP5b concen-
trations, and labeled adaptive bone formation were determined
using a one-way ANOVA with a Dunnett post-hoc test; the
Baseline group served as the control. Planned comparisons were
used to determine differences between the CGRP and CGRP8–37
groups. The Kruskal-Wallis ANOVA test and the Mann-Whitney
U test were use to analyze Rs.Sp.Dn and Cr.S.Dn. Results were
considered significant at p,0.05. Data are reported as mean 6
standard error of the mean or median and range for non-
parametric data.
Results
The number of cycles required to reach 47615% loss of stiffness
in fatigue-loaded ulnae was 3,73862,472, with a final peak load of
224.064.0N. A minimally displaced intracortical stress fracture
was noted in 31 of the 32 fatigue-loaded ulnae evaluated for
microdamage; as expected, no intracortical fatigue damage was
seen in the contralateral ulnae.
Infusion of CGRP elevated plasma CGRP concentrations
but did not influence plasma TRAP5b
Plasma CGRP concentrations were measured to verify
functional infusion of CGRP in the CGRP treatment group.
Plasma CGRP was elevated in the CGRP group compared with
the CGRP8–37 group (p=0.05), but not the Saline group (p,0.07)
(Fig. 2A). Plasma TRAP5b concentrations were not altered as a
result of CGRP or CGRP8–37 administration (p=0.41) (Fig. 2B).
Cyclic fatigue loading increased bone CGRP
concentrations in loaded and contralateral ulnae
To determine the effects of cyclic fatigue loading on bone
CGRP concentrations, we quantified CGRP in both the loaded
and contralateral ulnae of fatigue-loaded and control rats. The
concentration of CGRP was increased in both the loaded right
ulna (p,0.05) and the contralateral left ulna (p,0.05) of rats in the
Fatigue group, when compared to the Baseline group (Fig. 3). No
differences were seen between the Baseline group and the Sham
group (p=0.95). Additionally, no differences in humeral CGRP
concentrations were seen between groups.
Figure 3. Bone CGRP is increased by mechanical loading. Cyclic
fatigue loading of the right ulna resulted in increased CGRP
concentrations in both the fatigue-loaded (right) ulna and the
contralateral (left) ulna, when compared to the Baseline group. No
differences in CGRP concentrations were seen between the Sham group
and the Baseline group. The Fatigue group also had increased CGRP
concentrations compared to the Sham group. * 2p,0.05 versus the
relevant baseline control bone. Error bars represent standard error of
the mean. Baseline group n=12; Sham group n=12; Fatigue group
n=12.
doi:10.1371/journal.pone.0020386.g003
Figure 4. Targeted remodeling of bone microdamage. Photo-
micrographs of calcified transverse sections of ulna at 60% of bone
length, from proximal to distal [37]. Fatigue loading induced microcrack
formation and targeted remodeling. (A) Branching microcracks can be
appreciated histologically in fatigue-loaded bones. (B)T a r g e t e d
remodeling resulted in resorption space formation around the areas
of microcracking. Bones were bulk-stained with Villanueva bone stain.
Black arrows indicate fatigue damage; white asterisks are labeling
resorption spaces. Bar=0.5 mm.
doi:10.1371/journal.pone.0020386.g004
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bone remodeling in response to unilateral cyclic fatigue
loading
To quantify fatigue damage and associated osteoclast activa-
tion in rats treated with CGRP or CGRP8–37,w em e a s u r e d
Cr.S.Dn and Rs.Sp.Dn in both fatigue-loaded right ulnae and
the contralateral left ulnae (Fig. 4). No differences in Cr.S.Dn
were seen between groups (Fig. 5A). Rats in the CGRP8–37 group
had increased Rs.Sp.Dn in their right ulna 10 days after fatigue
loading, compared to the CGRP group (p,0.001), and the
Saline group (p,0.01) (Fig. 5B). In the contralateral left ulna,
Rs.Sp.Dn was increased to a small extent in the CGRP group,
compared to both the Saline group (p,0.001) and CGRP8–37
group (p,0.001).
Figure 5. Remodeling of fatigue loaded bone was increased with administration of CGRP8–37. Treatment with either saline, CGRP or
CGRP8–37 for 10 days after cyclic fatigue loading of the right ulna did not affect crack surface density (Cr.S.Dn), but resulted in altered resorption space
density (Rs.Sp.Dn). (A) Cr.S.Dn was similar between groups. (B) Rs.Sp.Dn in the right ulna was increased in the CGRP8–37 group compared to the CGRP
group and the Saline group. In the left ulna, resorption space number density was increased in the CGRP group, compared to the Saline group and
the CGRP8–37 group. ** 2p,0.01; *** 2p,0.001; versus the relevant saline control bone. Error bars represent range. Saline group n=8; CGRP group
n=12; CGRP8–37 group n=12.
doi:10.1371/journal.pone.0020386.g005
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increased reparative bone formation after unilateral
cyclic fatigue loading
The effect of CGRP and CGRP8–37 on load-induced bone
formation after cyclic fatigue was evaluated in both the fatigue-
loaded right ulnae and contralateral left ulnae. Rats treated with
either CGRP or CGRP8–37 for 10 days after cyclic fatigue
loading had increased reparative bone formation, when com-
pared to the rats that were treated with saline (Fig. 6). Ps.L.B.Ar
was increased in the right ulnae of the CGRP (p,0.001) and the
CGRP8–37 (p,0.001) groups, and in the left ulna of the CGRP8–
37 group (p,0.0001), when compared to the Saline group;
Ps.L.B.Ar was also increased in the left ulna of the CGRP8–37
group when compared to the CGRP group (Fig. 7A, p,0.05).
Similarly, Tt.L.B.Ar was increased in the right ulnae of the
CGRP (p,0.001) and the CGRP8–37 (p,0.0001) groups, and in
the left ulna of the CGRP8–37 group (p,0.05), when compared to
the Saline group (Fig. 7B). Es.L.B.Ar was also increased in the
right ulna of the CGRP (p,0.05) and the CGRP8–37 (p,0.001)
groups, when compared to the Saline group (Fig. 7C). No
differences in humeral bone formation were seen between any of
the groups.
Discussion
CGRP has been recognized as a neurotransmitter involved in
the regulation of bone remodeling and fracture healing [39,40].
However, the potential effects of CGRP signaling on skeletal
responses to bone loading and stress injury have not been
investigated. In the present study, using the rat ulna end-loading
model to induce cyclic fatigue in a single bone, we determined
how CGRP and the CGRP1 receptor antagonist, CGRP8–37,
influenced skeletal repair respons e st os t r e s si n j u r y ,i n c l u d i n g
bone remodeling and load-induced bone new formation. We
also determined how cyclic fatigue loading influenced bone
CGRP concentrations both locally and at distant skeletal sites.
We found that bone CGRP concentrations were increased after
unilateral fatigue loading in both loaded and contralateral
ulnae. We also found that both CGRP and CGRP8–37
augmented new bone formation in response to fatigue but did
not influence plasma TRAP5b concentrations. As expected,
plasma CGRP concentrations were higher in rats given
supplementary CGRP, as compared to rats that were treated
with saline or CGRP8–37.
TRAP5b is a marker of bone remodeling [41]. Both immature
and mature osteoclasts express TRAP5b, and plasma concentra-
tions of TRAP5b are proportional to osteoclast number [42]. Our
data shows that systemic administration of CGRP or CGRP8–37
did not affect TRAP5b concentrations in plasma, suggesting that
10 days after fatigue loading, overall numbers of activated
osteoclasts in each group were not influenced by these treatments.
Previous work from our laboratory has suggested that TRAP5b
serum concentrations may be neuronally-regulated in fatigue-
loaded male rats [43]. The data from this study suggest that
neuronal signaling effects on plasma TRAP5b are not associated
with CGRP signaling in sensory nerve fibers. It should be noted
that TRAP5b levels were measured 10 days after fatigue loading;
in future work it would be interesting to investigate markers of
bone remodeling throughout a 10 day adaptive period, as the
effect of CGRP on osteoclast activation may be more prominent
earlier in the experimental period after bone loading.
CGRP-immunoreactive nerve fibers are widely distributed
throughout bone [12,44,45]. During fracture healing, newly
formed CGRP fibers can be found in areas with high bone
formation rates [40]. The increase in CGRP concentrations 10
days after cyclic fatigue loading of the right ulna likely reflects
altered release of CGRP from sensory nerve endings in loaded
bone. Furthermore, the increase in CGRP concentrations in the
contralateral ulna 10 days after loading supports the concept that
mechanical loading of a single long bone may influence skeletal
Figure 6. Reparative bone formation induced by fatigue loading was increased after treatment with CGRP or CGRP8–37. Confocal
photomicrographs of calcified transverse sections of ulna at 60% of bone length, from proximal to distal [37]. Administration of either CGRP or
CGRP8–37 for 10 days after cyclic fatigue loading of the right ulna increased reparative bone formation in the loaded ulna compared with saline-
treated rats. Endosteal bone formation was particularly evident after CGRP8–37 treatment. Rats treated with CGRP8–37 also had greater bone formation
in the contralateral (left) ulna, which was not loaded, when compared to the left ulna of the saline-treated rats. New bone formation was double
labeled with calcein. White arrows indicate periosteal new woven bone formation; pink arrows indicate endosteal new bone. Bar=250 mm. Cr, cranial;
Cd, caudal; Med, medial; Lat, lateral. Saline group, n=8; CGRP group n=12; CGRP8–37 group, n=12.
doi:10.1371/journal.pone.0020386.g006
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We hypothesize that the CGRP in the contralateral bone is likely
derived from the peptidergic sensory innervation of bone
[12–15]. It is also possible that bone cells themselves may act
as a source of CGRP, although expression in bone cells occurs at
a low level [46]. It is well established that cyclic fatigue loading
induces a repair response in the rat ulna loading model [37,47].
Previous work from our laboratory has suggested that loading a
single bone may result in a systemic neurovascular response and
increased bone formation in distant skeletal long bones, and that
these changes are neuronally regulated [9,43,47]. CGRP may
thus be part of a previously unrecognized neuronal mechanism
that regulates skeletal responses to cyclic mechanical loading. In
the first experiment in which we studied CGRP concentrations in
bone after loading [9], we found decreased bone CGRP
concentrations after loading without bone fatigue. Thus, it
appears that the release of CGRP into bone tissue is modulated
by the intensity and pattern of the applied mechanical signal.
However, it is also possible that our results could be influenced by
the methodology used to isolate neuropeptides from bone, as we
used a different peptide isolation method in the previous study.
Interestingly, we found that systemic administration of CGRP
and CGRP8–37 over a 10 day period after unilateral fatigue
loading increased bone formation in the periosteal, endosteal and
intracortical envelopes. The increase in reparative bone formation
with CGRP administration was anticipated; CGRP has been
shown to be an inhibitor of bone resorption [48], and increases
osteogenesis in a dose-dependent manner [49].
CGRP8–37 principally antagonizes signaling via the CGRP1
receptor [20,23,24]. This receptor is well defined as a heterodimer
of the calcitonin receptor-like receptor (CRLR) and receptor
activity modifying protein 1 (RAMP1) [23,50]. In addition, CGRP
is also thought to signal through a putative CGRP2 receptor [23].
In rodents, CGRP binds to variants of both adrenomedullin (AM)
(AM2 consisting of CRLR and RAMP3) and amylin (AMY)
receptors (AMY1(a), AMY3(a)) [23,51,52]. AMY1(a) consists of
RAMP1 and an insert negative form of the calcitonin receptor
(CTR), while AMY3(a) consists of RAMP3 and the same CTR
variant [23,52]. Thus the ‘CGRP2 receptor’ may in reality be an
amalgamation of contributions from a variety of CGRP-activated
receptors [23].
As CGRP has been shown to activate bone formation, it is not
surprising that CGRP-a knockout mice are osteopenic [32]. The
increase in bone formation in rats treated with CGRP8–37,
however, was an unexpected result. The heterogeneity of CGRP
receptor signaling may explain this observation, and suggests that
signaling via a CGRP receptor that is not CGRP1 is responsible
for the load-induced osteogenic response. However, CGRP also
has actions on multiple organ systems, and it is also possible that
the effect of CGRP on vascular tone may help explain this result
[53–58]. Increased bone blood flow precedes bone repair in
response to fatigue loading, and remodeling in response to
decreased mechanical loading [47,58]. Systemic administration
of CGRP also decreases blood pressure in a dose-dependent
manner [59]. Therefore, treatment with CGRP8–37 may have
increased intraosseus pressure, transcortical interstitial fluid flow,
and associated bone formation [60,61], although such an effect
appears less likely in our model since we did not detect significant
changes in humeral bone formation with CGRP or CGRP8–37
treatment.
As expected, 10 days after cyclic fatigue loading there were no
differences in Cr.S.Dn between groups, indicating that rats in
each group experienced a similar degree of fatigue damage
during bone loading. However, we found that treatment with
CGRP8–37 did have a significant effect on osteoclast recruitment
and activation for targeted remodeling in the fatigue-loaded ulna;
targeted remodeling in the fatigue-loaded ulna was increased
after treatment with CGRP8–37. CGRP-immunoreactive nerve
fibers have direct contact with osteoclasts [18]. CGRP is an
inhibitor of bone resorption, possibly through interference with
the action of the receptor activator of NF-kB (RANKL), and thus
differentiation and recruitment of osteoclast precursors [48,62].
Our results suggest the CGRP1 receptor is responsible for this in-
vivo effect, such that in fatigue-loaded rats treated with the
CGRP8–37, the normal inhibition of CGRP on osteoclast
activation for targeted remodeling appears diminished. Interest-
ingly, this effect was detected in the face of increased bone CGRP
concentrations in both loaded and contralateral ulnae at 10 days
and a lack of difference in plasma TRAP5b between groups,
suggesting that the signals regulating targeted remodeling of
damaged bone are complex, and may involve other pathways
that activate osteoclastic bone remodeling. CGRP signaling may
have greater effects on osteoclastic activation, and a lesser effect
on osteoclastic recruitment and proliferation in vivo. We also
detected a small CGRP treatment effect on remodeling in the
contralateral ulna; the biological significance of this observation is
unclear.
A limitation to this study is that we analyzed bone CGRP
concentrations and bone repair at a single time point, 10 days after
fatigue loading. Additionally, it is not possible to fully isolate direct
effects of CGRP signaling on bone cells from effects of CGRP on
neuronal signaling, and possibly bone blood flow. As both CGRP
and CGRP8–37 augmented reparative bone formation, our data
suggest that CGRP release from nerve endings during bone
loading acts to modulate load-induced skeletal repair. Our results
implicate the CGRP1 receptor as responsible for effects on
osteoclasts, and a CGRP receptor that is not CGRP1 as
responsible for the osteogenic effects we observed.
In conclusion, our data support the established hypothesis that
CGRP is osteoanabolic to the skeleton in that it acts to increase
osteogenesis and inhibit osteoclastic bone resorption in vivo in a
bone fatigue model. The present study also suggests that CGRP
has regulatory effects on skeletal responses to mechanical loading.
Our results suggest that CGRP augments load-induced bone
formation and inhibits osteoclastic remodeling through increased
release of CGRP from the peptidergic sensory innervation of bone
tissue that is being repaired. Future work should confirm whether
or not mechanical loading of the skeleton leads to up-regulation of
Figure 7. Calcein-labeled new bone formation in response to unilateral cyclic fatigue loading of the right ulna in rats. Treatment with
either CGRP or CGRP8–37 for 10 days after fatigue loading the right ulna resulted in increased reparative bone formation in the loaded ulna in both
treatment groups; treatment with CGRP8–37 also significantly influenced labeled bone formation in the contralateral ulna, when compared to saline
treated rats. (A) Periosteal labeled bone area (Ps.L.B.Ar) was increased in the right ulnae of both treatment groups, and the left ulna of the CGRP8–37
treatment group, when compared to the saline treated group. (B) Total labeled bone area (Tt.L.B.Ar) was also increased in the right ulnae of both
treatment groups, and the left ulna of the CGRP8–37 treatment group, when compared to the saline treated group. (C) Endosteal labeled bone area
(Es.L.B.Ar) was increased in the right ulna of both the CGRP and CGRP8–37 treatment groups, when compared to the saline treated group. . * 2p,0.05;
** 2p,0.01; *** 2p,0.001 versus the relevant saline control bone. Error bars represent standard error of the mean. Saline group, n=8; CGRP group
n=12; CGRP8–37 group n=12.
doi:10.1371/journal.pone.0020386.g007
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occur during nociception [63], and also determine which CGRP
receptors are responsible for these actions.
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